by Rakovina Therapeutics | Apr 30, 2025 | Uncategorized
Vancouver, British Columbia, April 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its...
by Rakovina Therapeutics | Apr 29, 2025 | Uncategorized
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...
by Rakovina Therapeutics | Apr 29, 2025 | Uncategorized
Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of...
by Rakovina Therapeutics | Apr 22, 2025 | Uncategorized
Vancouver, British Columbia, April 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate...
by Rakovina Therapeutics | Mar 27, 2025 | Uncategorized
Cutting-Edge Research Results Showcase AI-Powered Drug Discovery Vancouver, British Columbia, Mar 25, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence...
by Rakovina Therapeutics | Mar 12, 2025 | Uncategorized
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignancies Vancouver, British Columbia, March 12, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company...